MOUNJARO 7.5mg (Tirzepatide PFS) 7.5mgx0.5 ml

Tirzepatide, the active ingredient in MOUNJARO 7.5mg, works by activating both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual action enhances glucose-dependent insulin secretion, reduces glucagon release, and slows gastric emptying, thereby improving glycemic control.

The usual dose of MOUNJARO 7.5mg is determined by a healthcare provider based on individual patient needs. The dosage is typically started at a lower strength and gradually increased to 7.5mg once weekly, as tolerated, to achieve optimal glycemic control.

The safety of MOUNJARO 7.5mg during pregnancy or breastfeeding has not been established. It is important to consult a healthcare provider before using this medication if you are pregnant, planning to become pregnant, or breastfeeding.

To order MOUNJARO 7.5mg from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. The team will ask you to confirm your trade or institutional credentials and will then provide pricing, availability, shipping, and the necessary import paperwork.

MOUNJARO 7.5mg is a dual GIP/GLP-1 receptor agonist, which distinguishes it from other diabetes medications that may target only one of these receptors. This dual action can provide more comprehensive glycemic control. However, the choice of medication depends on individual patient needs and should be discussed with a healthcare provider.

MOUNJARO 7.5mg should be stored at 2-8°C (36-46°F) in the original carton to protect from light. It can be stored unrefrigerated at temperatures not to exceed 30°C (86°F) for up to 21 days if needed. Do not freeze or shake the medication. Always handle the pre-filled syringe with care to avoid damage.

MOUNJARO 7.5mg is administered subcutaneously (under the skin) in the abdomen, thigh, or upper arm. It is typically injected once weekly at any time of day, with or without meals. A healthcare provider or trained professional should demonstrate the correct administration technique.

The most serious risks associated with MOUNJARO 7.5mg include pancreatitis, hypoglycemia, gallbladder problems, kidney problems, and allergic reactions. Patients should be monitored for these risks and report any severe or persistent symptoms to their healthcare provider immediately.

MOUNJARO 7.5mg should not be used by individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It is also not recommended for patients with type 1 diabetes mellitus or a history of severe hypersensitivity to tirzepatide or any of its excipients. Always consult a healthcare provider before starting this medication.